Sit Less, Interact and Move More (SLIMM) 2 Study

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age20+
SponsorSrinvasan Beddhu

About this trial

* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.

Eligibility criteria

Qualifiers

Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to <60 mL/min/1.73m²

Able to perform resistance training

Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop

Disqualifiers

Type 1 Diabetes

History of gastroparesis or paralytic ileus

At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer

Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.

Trial design

Treatments tested in this trial

  • SLIMM
  • Standard Resistance Training
  • Guided Resistance Training
  • Placebo
  • Semaglutide

Treatment groups

156 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Srinvasan Beddhu

Lead sponsor

University of Utah

Sponsor institution

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Stanford University

Collaborator